Laparoscopic Cholecystectomy
Conditions
Interventions
LVFX500mg single dose
LVFX500mg 3days
Sponsors
Kyoto Prefectural University of Medicine Division of Digestive Surgery, Department of Surgery
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: laparoscopic cholecystectomy Patients who undersutand the study and agree with written informed consent.
Exclusion criteria
Exclusion criteria: Patients have been treated with other antibiotics before the start of study drug administration Patients were treated with quinolone antibacterial agent within one week before the start of study drug administration Treatment with oral administration in patients with severe infection is not expected to effect Complications have serious underlying disease, patients have difficulty assessing the safety and efficacy of drug testing Patients with a history of allergy to quinolone antibacterials Patients with Severe cardiac dysfunction, liver dysfunction Patients with severe renal impairment Patients with a history of epilepsy or other seizure disorder Pregnant women and lactating women and the women are pregnant may Patients who are considered unsuitable for the doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of surgical site infection | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood and Bile concentrations of LVFX | — |
Countries
Japan
Contacts
Public ContactHisashi Ikoma
Kyoto Prefectural University of Medicine Division of Digestive Surgery, Department of Surgery
Outcome results
None listed